



*For immediate release 07.00: 14 July 2014*

**RETROSCREEN VIROLOGY GROUP PLC**  
("Retroscreen" or the "Company")

**BOARD CHANGE**

Retroscreen Virology Group plc (AIM: RVG), the pioneer of *hVIVO* human challenge models of disease, is pleased to announce that Dr Alison Fielding has been appointed as a Non-Executive Director of the Company with immediate effect.

Alison is a highly respected, entrepreneurial leader, executive coach and mentor with extensive board experience in both Executive and Non-Executive capacities in public, private and not-for-profit sectors. She has a track record of creating and building high-performing companies based on scientific innovation.

Alison is Director of IP Impact at IP Group plc, a leading UK intellectual property commercialisation company. She co-founded Techtran Group Limited and was the Chief Operating Officer of Techtran when it was acquired by IP Group in January 2005. She was a Director of IP Group from January 2005 to June 2013, promoted to Chief Technology officer in March 2007 and then Chief Operating Officer in May 2011. She spent six years at McKinsey & Co from 1994 to 2000, where she consulted primarily to the pharmaceutical and health care sectors. Prior to McKinsey, she spent four years as a development chemist for Zeneca, performing technical roles in the speciality chemicals and agrochemicals divisions. Alison holds an MBA from Manchester Business School, a Ph.D. in Organic Chemistry and a first class degree in Chemistry from the University of Glasgow.

Kym Denny, Chief Executive Officer, commented, "I am delighted to welcome Alison to Retroscreen's newly shaped Board, at this exciting juncture in the Company's development. Alison has a tremendous track record of working with growth companies in the life science sector to achieve their potential. We look forward to benefitting from her expertise, as we actively broaden Retroscreen's capabilities in our quest to leverage fully our unique *hVIVO* technology platform."

Dr Alison Margaret Fielding (49) is a director/ partner or has been a director/ partner of the following companies/ partnerships during the previous five years:

Current

Getech Group plc  
Green Chemicals plc  
Perachem Limited  
Tissue Regenix Group plc

Previous

Amaethon Limited  
Amaethon Trustees Limited  
Care International UK  
COE Group plc  
Crysalin Limited  
Fusion IP plc  
IP Group Plc

IP2IPO Limited  
IP2IPO Services Limited  
IP Industry Partners Limited  
Techtran Group Limited  
Techtran Limited  
Techtran Corporate Finance Limited  
Techtran Investments Limited  
Techtran Services Limited  
Pure Polymers Limited  
Top Technology Ventures Limited  
The Foundation for Social Entrepreneurs

Dr Fielding holds 24,320 ordinary shares in the Company, which were acquired prior to the Company's IPO in May 2012.

Save for the information disclosed above there is no other information to be disclosed on Dr Fielding under Schedule 2(g) of the AIM Rules.

**For further information please contact:**

**Retroscreen Virology Group plc** +44 207 756 1300

Kym Denny (CEO)  
Graham Yeatman (FD)

**Numis Securities Limited** +44 207 260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)  
James Black / Michael Burke (Corporate Broking)

**Notes to Editors:**

Retroscreen Virology Group plc ("Retroscreen") is a rapidly growing UK life sciences company pioneering a technology platform called *hVIVO* which uses human models of disease involving healthy volunteers to study new drugs and investigate disease in a safe, controlled environment.

Retroscreen has established itself as the world leader in this field through the provision of clinical services to third party study sponsors. To date, the Company has conducted over 35 clinical studies, involving more than 1600 volunteers for a range of leading industry, governmental and academic clients.

However, Retroscreen's *hVIVO* platform has a much wider application in helping to understand illness better because the Company believes that the best way to understand human disease is by studying it in humans, not laboratory models.